|View printer-friendly version|
Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
Poster B96, entitled Pharmacodynamic studies of SB 11285, a systemically bioavailable STING agonist in orthotopic tumor models, provides details on the self-assembly of SB 11285 into nanostructures that facilitate uptake into immune cells. This poster also highlights that SB 11285 caused significant induction of type I interferon and other cytokines for anti-tumor activity in multiple orthotopic and subcutaneous mouse models.
Poster B88, entitled SB 11312, an active metabolite of SB 11285, is a potent and systemically bioavailable STING agonist, highlights the anti-tumor activity and favorable safety profile of SB 11312 when administered by both the IT and IV routes, as well as the synergistic activity of SB 11312 when combined with anti-PD1 antibody in syngeneic mouse models.
Poster B87, entitled Mechanistic insights into the anti-tumor activity of SB 11285 – a novel STING agonist, provides insights into the mechanism of action of SB 11285 and its analogs and describes the binding of SB 11285 to wild type and polymorphic variants of STING. This poster also provides details on the dose-dependent production of type I IFNs, type II IFNs, other cytokines and chemokines by SB 11285 in human PBMCs.
All posters will be presented today from
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of the company’s trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.